Related Experiment Video

Updated: Jun 6, 2026

An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

Finasteride metabolism and pharmacogenetics: new approaches to personalized prevention of prostate cancer

Sarah L Hulin-Curtis1, Dominique Petit, W Douglas Figg

  • 1University of Sydney, Bosch Institute, Camperdown, New South Wales, Australia.

Future Oncology (London, England)
|December 15, 2010
PubMed

Insights

Finasteride is a prostate cancer prevention drug with variable success due to genetic factors. Understanding these genetic variations can lead to personalized medicine for finasteride treatment.

Area of Science:

  • Pharmacogenomics
  • Oncology
  • Molecular Endocrinology

Background:

  • Prostate cancer incidence is rising globally, necessitating effective prevention strategies.
  • Finasteride, a 5α-reductase type II inhibitor, shows variable efficacy in prostate cancer prevention.
  • Interindividual differences in finasteride response are attributed to heritable factors.

Purpose of the Study:

  • To elucidate the molecular mechanisms of finasteride, including its metabolism, excretion, and interactions.
  • To review genetic variations in steroid-metabolizing genes and their association with finasteride efficacy.
  • To identify research directions for personalized medicine in finasteride prevention.

Main Methods:

  • Literature review of finasteride metabolism and pharmacogenetics.
  • Analysis of genetic variations in steroid-metabolizing genes.
  • Synthesis of existing data on finasteride efficacy and heritability.

Main Results:

  • Finasteride's efficacy is influenced by its metabolism and interaction with endogenous steroids.
  • Genetic variations in steroid-metabolizing genes correlate with finasteride response.
  • Heritable factors significantly contribute to the variability in finasteride's preventive effects.

Conclusions:

  • Understanding finasteride's molecular mechanisms and genetic underpinnings is crucial.
  • Genetic profiling may predict finasteride response, enabling personalized treatment.
  • Further research into pharmacogenomics will advance personalized medicine for prostate cancer prevention.

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...